Last reviewed · How we verify
Hyperbaric Levobupivacaine 0.75%
Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Spinal anesthesia for surgical procedures, Regional anesthesia for lower limb and lower abdominal surgery.
At a glance
| Generic name | Hyperbaric Levobupivacaine 0.75% |
|---|---|
| Also known as | Bupinest 0.75% Pesado |
| Sponsor | Fundacion Clinica Valle del Lili |
| Drug class | Local anesthetic (amide class) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Levobupivacaine is the S-enantiomer of bupivacaine, a long-acting amide local anesthetic. It works by reversibly binding to and blocking voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and conduction of nerve impulses. The hyperbaric formulation (containing dextrose) increases the density of the solution, allowing for more controlled spinal distribution during intrathecal administration.
Approved indications
- Spinal anesthesia for surgical procedures
- Regional anesthesia for lower limb and lower abdominal surgery
Common side effects
- Hypotension
- Bradycardia
- Headache (post-dural puncture)
- Nausea
- Neurological toxicity (at high doses)
Key clinical trials
- Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia (PHASE4)
- Hyperbaric Bupivacaine and Hyperbaric Levobupivacaine in C/S (PHASE4)
- Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperbaric Levobupivacaine 0.75% CI brief — competitive landscape report
- Hyperbaric Levobupivacaine 0.75% updates RSS · CI watch RSS
- Fundacion Clinica Valle del Lili portfolio CI